https://doi.org/10.4081/monaldi.2024.2888
Respiratory syncytial virus: an overview of clinical manifestations and management in the Indian pediatric population
Submitted: December 26, 2023
Accepted: August 7, 2024
Published: October 4, 2024
Accepted: August 7, 2024
Abstract Views: 489
PDF_EARLY VIEW: 170
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Respiratory syncytial virus (RSV) plays a major part in causing lower respiratory tract infections in younger populations, especially in infants and pediatric patients, causing a higher rate of morbidity and mortality in the respective population, affecting 60% of the population globally. Typically, identifying the virus in the patient's respiratory secretions is important for laboratory validation of a clinically suspected RSV infection. Unfortunately, the only available preventive measure to lower the incidence for infants who are at high risk of RSV-induced hospitalization is palivizumab prophylaxis. Treatment strategies to manage RSV involve using an antiviral drug that is Ribavirin along with bronchodilators, nebulized adrenaline (epinephrine), and nebulized hypertonic saline. Providing patients with alternative treatment options like vitamin D-cathelicidin as well as probiotics and prebiotics can help reduce the intensity of the infection. This review article focuses on the epidemiology, clinical manifestation, prophylaxis, and available treatment options for RSV infections in infants, children, and young adults.
Furness JC, Habeb A, Spencer DA, O’Brien CJ. To the editor: bronchoalveolar lavage (BAL) in pediatric cystic fibrosis (CF): its clinical use modified by audit in a regional CF center. Pediatr Pulmonol 2002;33:234.
DOI: https://doi.org/10.1002/ppul.10052
Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus - a comprehensive review. Clin Rev Allergy Immunol 2013;45:331-9.
DOI: https://doi.org/10.1007/s12016-013-8368-9
Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev 2014;35:519-30.
DOI: https://doi.org/10.1542/pir.35.12.519
Taleb SA, al Thani AA, al Ansari K, Yassine HM. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches. Eur J Clin Microbiol Infect Dis 2018;37:1817-27.
DOI: https://doi.org/10.1007/s10096-018-3289-4
Simões EAF, Center KJ, Tita ATN, et al. Prefusion F protein–based respiratory syncytial virus immunization in pregnancy. N Engl J Med 2022;386:1615-26.
DOI: https://doi.org/10.1056/NEJMoa2106062
Campbell PT, Geard N, Hogan AB. Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting. BMC Med 2020;18:319.
DOI: https://doi.org/10.1186/s12916-020-01783-8
Riddell CA, Bhat N, Bont LJ, et al. Informing randomized clinical trials of respiratory syncytial virus vaccination during pregnancy to prevent recurrent childhood wheezing: A sample size analysis. Vaccine 2018;36:8100-9.
DOI: https://doi.org/10.1016/j.vaccine.2018.10.041
Silvestri M, Marando F, Costanzo AM, et al. Respiratory syncytial virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in italy: a retrospective analysis from the Osservatorio Study. Ital J Pediatr 2016;42:40.
DOI: https://doi.org/10.1186/s13052-016-0252-9
Popow-Kraupp T, Aberle JH. Diagnosis of respiratory syncytial virus infection. Open Microbiol J 2011;5:128-34.
DOI: https://doi.org/10.2174/1874285801105010128
Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis practice gaps.
Broor S, Parveen S, Maheshwari M. Respiratory syncytial virus infections in India: epidemiology and need for vaccine. Indian J Med Microbiol 2018;36:458-64.
DOI: https://doi.org/10.4103/ijmm.IJMM_19_5
Petrocelli PA, Cunsolo V, Melito M, et al. Diagnosis of respiratory syncytial virus (RSV) infection in children by respiratory panel utilized during the COVID-19 pandemic. Annali Istituto Superiore Sanità 2023;59:31-6.
Caliendo AM. Multiplex PCR and emerging technologies for the detection of respiratory pathogens. Clin Infect Dis 2011;52:S326-30.
DOI: https://doi.org/10.1093/cid/cir047
Barr R, Green CA, Sande CJ, Drysdale SB. Respiratory syncytial virus: diagnosis, prevention and management. Ther Adv Infect Dis 2019;6:2049936119865798.
DOI: https://doi.org/10.1177/2049936119865798
Simoes EAF. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003;143:S118-26.
DOI: https://doi.org/10.1067/S0022-3476(03)00511-0
Abman SH, Ogle JW, Butler-Simon N, et al. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988;113:826-30.
DOI: https://doi.org/10.1016/S0022-3476(88)80008-8
MacDonald NE, Hall CB, Suffin SC, et al. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307:397-400.
DOI: https://doi.org/10.1056/NEJM198208123070702
Lin GL, Drysdale SB, Snape MD, et al. Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. Nat Commun 2021;12:5971.
DOI: https://doi.org/10.1038/s41467-021-25265-4
Brady MT, Byington CL, Davies HD, et al. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014;134:e620-38.
Hill-Ricciuti A, Walsh EE, Greendyke WG, et al. Clinical impact of healthcare-associated respiratory syncytial virus in hospitalized adults. Infect Control Hosp Epidemiol 2023;44:433-9.
DOI: https://doi.org/10.1017/ice.2022.128
Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017;390:946-58.
DOI: https://doi.org/10.1016/S0140-6736(17)30938-8
Weinstein RA, Hall CB. Nosocomial respiratory syncytial virus infections: the “cold war” has not ended. Clin Infect Dis 2000;31:590-6.
DOI: https://doi.org/10.1086/313960
Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020;383:415-25.
DOI: https://doi.org/10.1056/NEJMoa1913556
Bordi P, Del Re M, Tiseo M. Crizotinib resensitization by compound mutation. (2016). N Engl J Med 2016;374:1790.
DOI: https://doi.org/10.1056/NEJMc1601366
Donia A, Hassan SU, Zhang X, et al. Covid-19 crisis creates opportunity towards global monitoring & surveillance. Pathogens 2021;10:256.
DOI: https://doi.org/10.3390/pathogens10030256
McNally JD, McEvoy CT. Immunomodulatory therapy for the prevention and treatment of respiratory syncytial virus infection. Pediatr Allergy Immunol Pulmonol 2019;32:99-106.
Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022;399:2047-64.
DOI: https://doi.org/10.1016/S0140-6736(22)00478-0
Paes B, Mitchell I, Li A, Lanctôt KL. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis 2012;31:2703-11.
DOI: https://doi.org/10.1007/s10096-012-1617-7
Silver AH, Nazif JM. Bronchiolitis. Pediatr Rev 2019;40:568-76.
DOI: https://doi.org/10.1542/pir.2018-0260
Zhang L, Mendoza-Sassi RA, Klassen TP, Wainwright C. Nebulized hypertonic saline for acute bronchiolitis: a systematic review. Pediatrics 2015;136:687-701.
DOI: https://doi.org/10.1542/peds.2015-1914
McDade P. Assessing Clinical Outcomes of the 2014 American Academy of Pediatrics Bronchiolitis Guideline. 2018. Available from: https://repository.library.georgetown.edu/bitstream/handle/10822/1053077/McDade_georgetown_0076D_13809.pdf?sequence=1&isAllowed=y.
Zhang L, Mendoza-Sassi RA, Wainwright CE, et al. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev 2023;4:CD006458.
DOI: https://doi.org/10.1002/14651858.CD006458.pub5
How to Cite
B J, Abhishek, Agadi Hiremath Viswanatha Swamy, Sanatkumar Bharamu Nyamagoud, Anupama George, and Namratha D. 2024. “Respiratory Syncytial Virus: An Overview of Clinical Manifestations and Management in the Indian Pediatric Population”. Monaldi Archives for Chest Disease, October. https://doi.org/10.4081/monaldi.2024.2888.
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
